Lancet, DOI: 10.1016/s0140-6736(02)11079-8.
The Lancet, Volume 360, Issue 9338, Pages 971 – 977, 28 September 2002
Copyright © 2002 Elsevier Ltd All rights reserved.
Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial.
Dr Lut Van Damme MD (email@example.com), Gita Ramjee PhD:b, Michel Alary MD:c&d, Bea Vuylsteke MD:a&e, Verapol Chandeying MD:f, Helen Rees MD:g, Pachara Sirivongrangson MD:h, Léonard Mukenge Tshibaka MD:c&i, Virginie Ettiègne-Traoré MD:e, Charn Uaheowitchai MD:j, Salim S Abdool Karim MD:b, Benoît Mâsse PhD:c&k, Jos Perriëns MD:l, Marie Laga MD:a, on behalf of the COL-1492 study group. Study group members listed at end of report.
Nonoxynol-9 (rINN, nonoxinol-9) is an over-the-counter spermicide that has in-vitro anti-HIV-1 activity. Results of studies of its effectiveness in prevention of HIV-1 infection in women have been inconclusive. We aimed to assess effectiveness of this vaginal gel.
We did a randomised, placebo-controlled, triple-blinded, phase 2/3 trial with COL-1492, a nonoxynol-9 vaginal gel, in 892 female sex workers in four countries: Benin, Côte d’lvoire, South Africa, and Thailand. 449 women were randomly allocated nonoxynol-9 and 443 placebo. Primary endpoint was incident HIV-1 infection. Secondary endpoints included Neisseria gonorrhoeas and Chlamydia trachomatis infections. Analysis was by intention to treat.
765 women were included in the primary analysis. HIV-1 frequency in nonoxynol-9 users was 59 (16%) of 376 compared with 104 (27%) of 389 in placebo users (402·5 vs 435·0 woman-years; hazard ratio adjusted for centre 1·5; 95% Cl 1·0—2·2; p=0·047). 239 (32%) women reported use of a mean of more than 3·5 applicators per working day, and in these women, risk of HIV-1 infection in nonoxynol-9 users was almost twice that in placebo users (hazard ratio 1·8; 95% Cl 1·0—3·2). 516 (68%) women used the gel less frequently than 3·5 times a day, and in these, risk did not differ between the two treatments. No significant effect of nonoxynol-9 on N gonorrhoeas (1·2; 0·9—1·6) or C trachomatis (1·2; 0·8—1·6) infections was reported.
This study did not show a protective effect of COL-1492 on HIV-1 transmission in high-risk women. Multiple use of nonoxynol-9 could cause toxic effects enhancing HIV-1 infection. This drug can no longer be deemed a potential HIV-1-prevention method. Assessment of other microbicides should continue.
LIST OF STUDY GROUP MEMBERS:
a: Institute of Tropical Medicine, Antwerp, Belgium
b: Medical Research Council, Durban, South Africa
c: Groupe de Recherche en Epidémiologie, Centre Hospitalier Affilié Universitaire de Québec et Université Laval, Québec, Québec, Canada
d: Projet SIDA 2, Cotonou, Bénin
e: Projet RETRO-CI, Abidjan, Côte d’lvoire
f: Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand
g: Reproductive Health Research Unit, Department of Obstetrics and Gynaecology, University of the Witwatersrand, Johannesburg, South Africa
h: Ministry of Health, Venereal Disease Division, Bangkok, Thailand
i: Dispensaire Maladies Sexuellement Transmissibles, Centre de Santé de la Circonscription Urbaine de Cotonou 1, Cotonou, Benin
j: Venereal Disease Center Region 12, Songkla, Thailand
k: Fred Hutchinson Cancer Research Center, Seattle, WA, USA
l: UNAIDS, Geneva, Switzerland
Correspondence to: Dr Lut Van Damme, CONRAD, 1611 North Kent Street, Suite 806, Arlington, VA 22209, USA
Article published online at http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)11079-8/abstract#cor1 and appeared there on June 22, 2014.
Please note that while this site offers information, it should not be taken as medical advice.
Please consult a trusted medical professional before using the information on this site.
Results should be expected to vary from individual to individual. Also, please understand that you may still need to do other things to support your health in addition to using the information on this site as the information on this site is not intended for diagnosis or treatment.